Comments on the European Commission’s Pharmaceutical Strategy for Europe

This submission complements the Chamber’s ongoing support for the Commission’s work to remove trade barriers and to protect intellectual property (IP) in the European Union (EU) and internationally . The Chamber respectfully offers several suggestions for how Europe can begin to reclaim a leadership role and become a more attractive investment destination for biopharmaceuticals and ensure Europeans can access the very latest innovative medicines.